top of page

Biopharma Daily Stock Updates - 01/07/21

Updated: Jan 13, 2021

$XBI $149.21 (+4.11%) 📈


COVID:

$NVAX (+3.56%) - Novavax Finalizes Agreement with Commonwealth of Australia for 51 Million Doses of COVID-19 Vaccine

https://ir.novavax.com/news-releases/news-release-details/novavax-finalizes-agreement-commonwealth-australia-51-million


PIPELINE:

$SRPTA (+1.50%) - Sarepta Therapeutics Announces Top-line Results for Part 1 of Study 102 Evaluating SRP-9001, its Investigational Gene Therapy for the Treatment of Duchenne Muscular Dystrophy

https://investorrelations.sarepta.com/news-releases/news-release-details/sarepta-therapeutics-announces-top-line-results-part-1-study-102


$ALNY (+9.91%) - Alnylam Reports Positive Topline Results from HELIOS-A Phase 3 Study of Vutrisiran in Patients with hATTR Amyloidosis with Polyneuropathy

https://investors.alnylam.com/press-release?id=25366


$MRUS (-1.16%) - Merus Granted FDA Fast Track Designation of Zenocutuzumab for the Treatment of Patients with Neuregulin 1 Fusion Cancers

https://ir.merus.nl/news-releases/news-release-details/merus-granted-fda-fast-track-designation-zenocutuzumab-treatment


$GLYC (+4.32%) - APL-106 (uproleselan) Granted Breakthrough Therapy Designation in China for the Treatment of Acute Myeloid Leukemia

https://ir.glycomimetics.com/news-releases/news-release-details/apl-106-uproleselan-granted-breakthrough-therapy-designation


$ALDX (+26.42%) - Aldeyra Therapeutics Announces Positive Top-Line Symptom and Sign Results from Run-In Cohort of Phase 3 TRANQUILITY Trial in Dry Eye Disease

https://ir.aldeyra.com/news-releases/news-release-details/aldeyra-therapeutics-announces-positive-top-line-symptom-and


$BTNX (+2.78%) - BioNTech Publishes Data on Novel mRNA Vaccine Approach to Treat Autoimmune Diseases in Science

https://biontechse.gcs-web.com/news-releases/news-release-details/biontech-publishes-data-novel-mrna-vaccine-approach-treat


$AQST (+3.25%) - Aquestive Therapeutics Provides Business Update

https://investors.aquestive.com/news-releases/news-release-details/aquestive-therapeutics-provides-business-update


$DVAX (+6.52%) - Dynavax Announces Final Immunogenicity and Interim Safety Results from Clinical Trial Evaluating HEPLISAV-B in Patients Undergoing Hemodialysis

https://investors.dynavax.com/news-releases/news-release-details/dynavax-announces-final-immunogenicity-and-interim-safety


$KALA (+3.96%) - Kala Pharmaceuticals Announces Availability of EYSUVIS™ for the Treatment of Dry Eye Disease and Provides Update on Development Pipeline

https://investors.kalarx.com/news-releases/news-release-details/kala-pharmaceuticals-announces-availability-eysuvistm-treatment


$LOGC (+1.85%) - LogicBio Announces Extension Of Collaboration With Children's Medical Research Institute

https://investor.logicbio.com/news-releases/news-release-details/logicbio-announces-extension-collaboration-childrens-medical


$PRAX (+4.62%) - Praxis Precision Medicines Receives Rare Pediatric Disease and Orphan Drug Designations for Severe Pediatric Epilepsy Programs

https://investors.praxismedicines.com/news-releases/news-release-details/praxis-precision-medicines-receives-rare-pediatric-disease-and


FINANCIAL:

$CERC (+2.11%) - Cerecor Inc. Announces Pricing of $36.4 Million Public Offering of Common Stock and Pre-Funded Warrants

https://ir.cerecor.com/press-releases/detail/116/cerecor-inc-announces-pricing-of-36-4-million-public


$ARCT (+35.65%) - Wells Fargo Initiates Coverage On Arcturus Therapeutics with Overweight Rating

https://www.benzinga.com/news/21/01/19054722/wells-fargo-initiates-coverage-on-arcturus-therapeutics-with-overweight-rating


$AMRN (+9.69%) - Amarin Provides Preliminary 2020 Results and 2021 Outlook

https://investor.amarincorp.com/news-releases/news-release-details/amarin-provides-preliminary-2020-results-and-2021-outlook


$EIGR (-8.06%) - Eiger BioPharmaceuticals Updates on 2020 Progress and 2021 Plans https://ir.eigerbio.com/news-releases/news-release-details/eiger-biopharmaceuticals-updates-2020-progress-and-2021-plans


$RVNC (+8.79%) - Revance Provides Corporate Update and Anticipated Milestones for 2021 https://investors.revance.com/news-releases/news-release-details/revance-provides-corporate-update-and-anticipated-milestones-0



0 comments
bottom of page